BD&L strategy for oncology leadership
Authored by: Joseph Feingold
Over the last decade, oncology revenue growth for top pharma players has largely been driven by BD&L. Our experts take a deep dive into the growing oncology market uncovering the top drivers and activities of revenue growth.
Explore the full analysis, takeaways, and strategic recommendations for how to engage in BD&L to drive growth in oncology.
Contact us.
To speak with our experts, fill out the form below.
Jump to a slide with the slide dots.
ASH® 2025 roundtable: Turning hematology innovation into real world progress
Insights from ASH® 2025 on hematology innovation, CAR-T, bispecifics, diagnostics, and how connected strategy supports real-world adoption.
Read moreFrom High Hopes to Hesitation: Tracking the Shifting Barriers to Alzheimer’s DMT adoption
Why Alzheimer’s DMT uptake remains low: Explore key barriers, diagnostic gaps, and market insights from 783 physicians worldwide.
Read moreLaunch command centers predict pharma launch risk with agentic AI
Agentic AI–powered launch command centers predict pharma launch risks and enable faster, smarter decisions for successful product launches.
Read more